Both weekend warriors and steady exercisers had a significantly lower risk of premature death compared to inactive peoples, ...

Strokes caused by an artery tear are landing five times as many Americans in the hospital these days, a new study says.

A dose of an experimental drug reduced the levels of a fatal type of cholesterol for up to a year despite previous knowledge that it's untreatable. NBC News reported that pharmaceutical company Eli ...

A change in the monetary system presages a commodity bull market. Not only gold, but commodities generally will likely respond positively to what’s underway, advises Adrian Day, editor of Global ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

Eli Lilly’s experimental drug lepodisiran has shown a 94% reduction in lipoprotein(a) levels, a key genetic risk factor for ...

New drug shows promise in lowering Lp(a), a hidden heart risk factor. Especially vital for Black Americans, who often have ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...